Journal article
Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study
H Midgard, B Hajarizadeh, EB Cunningham, B Conway, M Backmund, P Bruggmann, J Bruneau, S Bourgeois, A Dunlop, GR Foster, M Hellard, G Robaeys, MC Thurnheer, M Weltman, J Amin, PS Marks, S Quiene, GJ Dore, O Dalgard, J Grebely
International Journal of Drug Policy | ELSEVIER SCIENCE BV | Published : 2017
Abstract
Background The risk of hepatitis C virus (HCV) reinfection due to continued injecting risk behaviours might remain a barrier to HCV treatment among people who inject drugs. We aimed to evaluate changes in risk behaviours during and following HCV treatment among people with ongoing injecting drug use or receiving opioid substitution treatment (OST). Methods ACTIVATE was an international multicentre clinical trial conducted between 2012 and 2014. Participants with HCV genotypes 2/3 infection were treated with peg-interferon/ribavirin for 12 or 24 weeks and completed a self-administered behavioural questionnaire at each study visit. The impact of time in treatment and follow-up on longitudinall..
View full abstractGrants
Funding Acknowledgements
The ACTIVATE study was supported in part by a research grant from the Investigator Initiated Studies Program of Merck Sharp & Dohme Corp. The Opinions expressed in this paper are those of the authors and do not necessarily represent those of Merck Sharp & Dohme Corp. The Kirby Institute is funded by the Australian Government Department of Health. The views expressed in this publication do not necessarily represent the position of the Australian Government. Havard Midgard is supported by research funding from the Norwegian ExtraFoundation for Health and Rehabilitation. Jason Grebely is supported by a National Health and Medical Research Council Career Development Fellowship. Gregory J Dore is supported by a National Health and Medical Research Council Practitioner Research Fellowship. Behzad Hajarizadeh is supported by a National Health and Medical Research Council Early Career Fellowship.